allergytalk

Episode 51 - Does Eosinophil Depletion Improve Eosinophilic Esophagitis?

Today we are joined by Dr. Iris Otani, an associate professor of medicine at UCSF and an assistant editor of Allergy Watch. We will be reviewing the November-December 2024 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

 

For information about CME credit, head over to http://education.acaai.org/allergytalk

 

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

 

Articles Reviewed:

Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices.

Forecasting daily total pollen concentrations on a global scale.

Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.

 

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

 

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 50 - Can Asthma Biologics Affect Vaccine Immunity?

Today we are joined by Dr. Iris Otani, an associate professor of medicine at UCSF and an assistant editor of Allergy Watch. We will be reviewing the November-December 2024 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

For information about CME credit, head over to http://education.acaai.org/allergytalk

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial.

Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study.

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 49 – The Mental Health Impact of Eczema and Food Allergies

Welcome to Season Three of AllergyTalk!

 

Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

 

For information about CME credit, head over to http://education.acaai.org/allergytalk

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

 

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

 

Articles Reviewed:

The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry. 

Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders. 

Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

 

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Hernandez Trujillo:

• Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda
• Consultant: Pharming, Kaleo
• Speaker: CSL, Takeda, Kaleo

Episode 48 - Can Blood Transfusions Trigger Food Allergy?

Welcome to Season Three of Allergytalk!

Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

For information about CME credit, head over to http://education.acaai.org/allergytalk

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins. 

Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food.

Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.

 

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Hernandez Trujillo:

• Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda
• Consultant/Speaker: Kaleo
• Consultant: Allergy & Asthma Network, Pharming
• Speaker: CSL, Takeda

 

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI

 

Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.

 

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Employ strategies for long-term prophylaxis.

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

 

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

 

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

 

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

 

This podcast miniseries is supported by a grant from Takeda.

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment

Episode 2: Overcoming Barriers in HAE Treatment

 

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI

 

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.

 

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Create effective treatment plans for their specific population (minority, rural, urban)

 

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

 

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

 

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

 

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

 

This podcast miniseries is supported by a grant from Takeda.

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies Miniseries Episode 1 – Diagnosing HAE Accurately

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI

This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Diagnose pediatric HAE accurately

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

 

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

 

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

 

This podcast miniseries is supported by a grant from Takeda.

Episode 47: Does Food Allergy Increase Cardiovascular Risk?

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

CRISPR Gene-Editing Therapy for Hereditary Angioedema

Reviewed by Samantha knox

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975.

New Peanut Allergy Rare After Peanut Introduction in Infants

Reviewed by Sarah Spriet

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.

 

IgE to Food Allergens and Cardiovascular Mortality

Reviewed by Gerry Lee

IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis

Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.

 

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)

Episode 46: Can We Achieve Clinical Remission In Asthma?

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Reviewed by Iris Otani

Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.

Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.

Clinical Remission in a Real-World Severe Asthma Registry

Reviewed by Tim Chow

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.

McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.

More Evidence Against Using Corticosteroids for Anaphylaxis

Reviewed by Iris Otani

Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.

Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries

Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma

 

Host: Gerald B. Lee, MD, FACAAI

Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

 

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.

 

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US
• Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
• Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
• Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

 

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

 

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

 

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

 

This podcast miniseries is supported by a grant from AstraZeneca.